BOSTON MEDICAL CENTER
- Type
- Teaching hospital
- Where
- South Boston, MA
- Medicare CCN
- 220031
- Received
- $3,586,676 in 298 records, 2019 ($615,903 general, $2,970,773 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Boston Medical Center Corporation Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Nonprofit contractor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Patent assignee: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Trademark owner: Boston Medical Center Corporation Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 58 | $615,903 |
| 2019 | Research payment | 240 | $2,970,773 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 240 | $2,970,773 |
| Grant | 8 | $444,412 |
| Education | 28 | $92,014 |
| Consulting Fee | 3 | $45,000 |
| Gift | 9 | $17,890 |
| Charitable Contribution | 4 | $8,050 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $5,000 |
| Space rental or facility fees (teaching hospital only) | 1 | $2,500 |
| Travel and Lodging | 3 | $925 |
| Food and Beverage | 1 | $108 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Gilead Sciences, Inc. | $59,464 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-31 | Philips North America LLC | $33,974 | Research payment | Cash or cash equivalent | Ingenia 3 0T R5 Device, Devices | 2019 | |
| 2019-12-31 | Roche Diagnostics Operations, Inc. | $16,786 | Research payment | Cash or cash equivalent | CD cobas Reagents Device, Centralized Diagnostics | RD001469 | 2019 |
| 2019-12-31 | KARL STORZ Endoscopy-America | $15,779 | Education | In-kind items and services | TELE PACK X LED,CCU/LIGHT SOURCE/MONITOR Device, VIDEOIMAGING | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $10,519 | Education | In-kind items and services | TELE PACK X LED,CCU/LIGHT SOURCE/MONITOR Device, VIDEOIMAGING | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $8,296 | Education | In-kind items and services | RINSE TUBE ASSEMBLY Device, OTHER MISC | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $7,325 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $6,074 | Education | In-kind items and services | ASM,HEAD,IMAGE1 S,H3-Z, CE Device, VIDEOIMAGING | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $5,937 | Education | In-kind items and services | ADAPTOR, C'MT, 30MM, CE Device, VIDEOIMAGING | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $5,584 | Education | In-kind items and services | HD,TELECAM-C'MT, NTSC, CE Device, VIDEOIMAGING | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $4,073 | Education | In-kind items and services | INSERT,SCISSORS,STRAIGHT,DBL Device, LAPAROSCOPY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $3,723 | Education | In-kind items and services | 7 FLAT PANEL MONITOR ONLY F/C-MAC, HDMI Device, ANESTHESIOLOGY | 2019 | |
| 2019-12-31 | Belmont Instrument LLC | $3,674 | Gift | Cash or cash equivalent | The Belmont buddy 2 Blood/Fluid Warmer Device, Blood Warmer | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $2,826 | Education | In-kind items and services | C-MAC POWER SUPPLY REPLACEMENT F/8403ZX Device, ANESTHESIOLOGY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $2,684 | Education | In-kind items and services | C-MAC POWER SUPPLY REPLACEMENT F/8403ZX Device, ANESTHESIOLOGY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $2,627 | Education | In-kind items and services | 26 inch LED MONITOR Device, VIDEOIMAGING | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $2,626 | Education | In-kind items and services | C-MAC POWER SUPPLY REPLACEMENT F/8403ZX Device, ANESTHESIOLOGY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $2,398 | Education | In-kind items and services | TROCAR SIZE 6MM, BLUNT TIP Device, LAPAROSCOPY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $2,213 | Education | In-kind items and services | TROCAR, SIZE 6MM Device, LAPAROSCOPY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $2,213 | Education | In-kind items and services | TROCAR, SIZE 6MM Device, LAPAROSCOPY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $2,003 | Education | In-kind items and services | 7 FLAT PANEL MONITOR ONLY F/C-MAC, HDMI Device, ANESTHESIOLOGY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $1,742 | Education | In-kind items and services | ROLLING POLE STAND FOR TELE PACK X Device, VIDEOIMAGING | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $1,053 | Education | In-kind items and services | ADAPTOR, C'MT, 30MM, CE Device, VIDEOIMAGING | 2019 | |
| 2019-12-31 | Roche Diagnostics Operations, Inc. | $767 | Research payment | In-kind items and services | CD cobas Reagents Device, Centralized Diagnostics | RD001469 | 2019 |
| 2019-12-31 | KARL STORZ Endoscopy-America | $728 | Education | In-kind items and services | 26 inch LED MONITOR Device, VIDEOIMAGING | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $634 | Education | In-kind items and services | POLE STAND FOR VIDEO INTUBATION PLATFORM Device, ANESTHESIOLOGY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $364 | Education | In-kind items and services | C-MAC POWER SUPPLY REPLACEMENT F/8403ZX Device, ANESTHESIOLOGY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $244 | Education | In-kind items and services | SCOPE HOLDER Device, ANESTHESIOLOGY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $162 | Education | In-kind items and services | LIGHT CABLE, 3.5MM X 300CM. LGTH 9.8 FT Device, VIDEOIMAGING | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $74 | Education | In-kind items and services | INSERT,DISSECT,RIGHT ANGLE,DBL Device, LAPAROSCOPY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $50 | Education | In-kind items and services | INSERT,DISSECT,RIGHT ANGLE,DBL Device, LAPAROSCOPY | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $25 | Education | In-kind items and services | VARIABLE HEIGHT SECONDARY MONITOR STAND Device, VIDEOIMAGING | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $11,752 | Research payment | Cash or cash equivalent | DARZALEX Biological, Oncology | A Phase I-II Trial of Daratumumab for the Treatment of Patients with AL amyloidosis | 2019 |
| 2019-12-26 | PFIZER INC. | $363,024 | Research payment | Cash or cash equivalent | BIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA | 2019 | |
| 2019-12-23 | Janssen Research & Development, LLC | $3,298 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-12-23 | ABBVIE INC. | $895 | Research payment | Cash or cash equivalent | M16-123 | 2019 | |
| 2019-12-19 | PFIZER INC. | $4,225 | Research payment | Cash or cash equivalent | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT W | 2019 | |
| 2019-12-19 | Bayer Healthcare Pharmaceuticals Inc. | $1,625 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2019 |
| 2019-12-18 | Roche TCRC, Inc. | $323 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | THE EFFECT OF 24WEEK TREATMENT WITH BASMISANIL ON COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA | 2019 |
| 2019-12-16 | Janssen Research & Development, LLC | $1,250 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-12-16 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-12-16 | Merck Sharp & Dohme LLC | $267 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2019 |
| 2019-12-12 | Janssen Research & Development, LLC | $25,721 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-12-12 | PFIZER INC. | $2,739 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-12-06 | Barco, Inc. | $187 | Gift | In-kind items and services | PS SM 90/264 120W 24V Device, Diagnostic Imaging | 2019 | |
| 2019-12-06 | Barco, Inc. | $187 | Gift | In-kind items and services | PS SM 90/264 120W 24V Device, Diagnostic Imaging | 2019 | |
| 2019-12-04 | Genentech, Inc. | $9,787 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PH II OLE OF GDC 0853 IN ERL | 2019 |
| 2019-11-29 | Merck Sharp & Dohme LLC | $16,239 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2019 |
| 2019-11-29 | Janssen Research & Development, LLC | $6,059 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-11-27 | PFIZER INC. | $66,229 | Research payment | Cash or cash equivalent | BIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA | 2019 | |
| 2019-11-27 | PFIZER INC. | $33,589 | Research payment | Cash or cash equivalent | BIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA | 2019 | |
| 2019-11-27 | Intercept Pharmaceuticals, Inc. | $1,503 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-11-23 | PFIZER INC. | $10,750 | Research payment | Cash or cash equivalent | ROBO2 ESOE | 2019 | |
| 2019-11-22 | PFIZER INC. | $66,702 | Research payment | Cash or cash equivalent | BIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA | 2019 | |
| 2019-11-21 | Conformis, Inc. | $6,565 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2019 |
| 2019-11-20 | Gilead Sciences, Inc. | $2,112 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Tra | 2019 |
| 2019-11-18 | ABBVIE INC. | $1,911 | Research payment | Cash or cash equivalent | M16-123 | 2019 | |
| 2019-11-18 | Bayer Healthcare Pharmaceuticals Inc. | $1,460 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2019 |
| 2019-11-18 | Boston Scientific Corporation | $516 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | PREEMPT HF | 2019 |
| 2019-11-15 | Otonomy, Inc. | $4,004 | Research payment | Cash or cash equivalent | Drug | A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Int | 2019 |
| 2019-11-12 | Incyte Corporation | $10,400 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-11-12 | Incyte Corporation | $4,225 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-11-12 | Incyte Corporation | $2,600 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-11-12 | Incyte Corporation | $1,284 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-11-07 | GUERBET LLC | $24,315 | Research payment | Cash or cash equivalent | Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging | 2019 | |
| 2019-11-05 | Takeda Pharmaceuticals U.S.A., Inc. | $13,618 | Research payment | Cash or cash equivalent | ENTYVIO Biological, Lower GI | Entyvio-Vedolizumab- Long Term Study | 2019 |
| 2019-10-31 | Janssen Research & Development, LLC | $5,015 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-10-29 | Gilead Sciences, Inc. | $65,000 | Research payment | Cash or cash equivalent | Determining the Burden, Heritability, and Clinical Implications of Increased Liver Stiffness from Fatty Liver Disease in | 2019 | |
| 2019-10-29 | Sysmex America, Inc. | $217 | Travel and Lodging | Cash or cash equivalent | XN Series Device, Hematology | 2019 | |
| 2019-10-28 | Emmaus Medical, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Endari Drug, Sickle Cell | 2019 | |
| 2019-10-22 | Allergan, Inc. | $5,000 | Research payment | Cash or cash equivalent | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICR | 2019 | |
| 2019-10-22 | Allergan, Inc. | $2,600 | Research payment | Cash or cash equivalent | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICR | 2019 | |
| 2019-10-22 | Allergan, Inc. | $2,100 | Research payment | Cash or cash equivalent | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICR | 2019 | |
| 2019-10-22 | Allergan, Inc. | $1,500 | Research payment | Cash or cash equivalent | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICR | 2019 | |
| 2019-10-21 | Janssen Research & Development, LLC | $250 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2019 | |
| 2019-10-16 | Intercept Pharmaceuticals, Inc. | $3,284 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-10-15 | Merck Sharp & Dohme LLC | $1,750 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2019 |
| 2019-10-15 | Merck Sharp & Dohme LLC | $750 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2019 |
| 2019-10-15 | Merck Sharp & Dohme LLC | $250 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2019 |
| 2019-10-11 | PFIZER INC. | $99,817 | Research payment | Cash or cash equivalent | BIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA | 2019 | |
| 2019-10-09 | PFIZER INC. | $66,703 | Research payment | Cash or cash equivalent | BIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA | 2019 | |
| 2019-10-09 | PFIZER INC. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-10-07 | GENZYME CORPORATION | $4,600 | Consulting Fee | Cash or cash equivalent | FABRAZYME Drug, RARE DISEASE GENETICS | 2019 | |
| 2019-10-07 | GENZYME CORPORATION | $4,600 | Consulting Fee | Cash or cash equivalent | FABRAZYME Drug, RARE DISEASE GENETICS | 2019 | |
| 2019-10-07 | Merck Sharp & Dohme LLC | $474 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2019 |
| 2019-10-04 | Integra LifeSciences Corporation | $955 | Research payment | Cash or cash equivalent | PRIMATRIX Device, RECON-SKIN AND WOUND | T-PMXDFU-01 | 2019 |
| 2019-10-02 | KLS-Martin L.P. | $50,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-10-02 | PFIZER INC. | $14,790 | Research payment | Cash or cash equivalent | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT W | 2019 | |
| 2019-10-02 | Genentech, Inc. | $1,500 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-10-01 | Celgene Corporation | $448 | Research payment | Cash or cash equivalent | RPC-1063 Drug | (RPC01-3101) PhIII RPC1063 Induction and Maintenance in Moderate to Severe UC TRUENORTH (BMS Study Number: IM047-P22) ( | 2019 |
| 2019-09-30 | Janssen Research & Development, LLC | $13,956 | Research payment | Cash or cash equivalent | DARZALEX Biological, Oncology | A Phase I-II Trial of Daratumumab for the Treatment of Patients with AL amyloidosis | 2019 |
| 2019-09-30 | ABBVIE INC. | $895 | Research payment | Cash or cash equivalent | M16-123 | 2019 | |
| 2019-09-30 | Roche Diagnostics Operations, Inc. | $602 | Research payment | In-kind items and services | CD cobas Reagents Device, Centralized Diagnostics | RD001469 | 2019 |
| 2019-09-27 | Janssen Research & Development, LLC | $5,015 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-09-24 | Merck Sharp & Dohme LLC | $348 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2019 |
| 2019-09-19 | Merck Sharp & Dohme LLC | $285 | Research payment | In-kind items and services | Characterization of Systemic and Local Immune Responses to Chlamydia Antigens in Women to support Vaccine Antigen Select | 2019 | |
| 2019-09-17 | Merck Sharp & Dohme LLC | $15,125 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2019 |
| 2019-09-11 | Bard Peripheral Vascular, Inc. | $2,304 | Gift | In-kind items and services | 2019 | ||
| 2019-09-10 | Bard Peripheral Vascular, Inc. | $4,237 | Gift | In-kind items and services | 2019 | ||
| 2019-09-09 | Bard Peripheral Vascular, Inc. | $5,023 | Gift | In-kind items and services | 2019 | ||
| 2019-09-07 | Olympus Corporation of the Americas | $6,762 | Grant | In-kind items and services | Olympus ENT Instruments Device, ENT Products | 2019 | |
| 2019-09-06 | Medical Device Business Services, Inc. | $440 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow-up | 2019 |
| 2019-09-06 | Aesculap, Inc. | $348 | Gift | Cash or cash equivalent | 2019 | ||
| 2019-09-05 | Janssen Research & Development, LLC | $877 | Research payment | Cash or cash equivalent | DARZALEX Biological, Oncology | A Phase I-II Trial of Daratumumab for the Treatment of Patients with AL amyloidosis | 2019 |
| 2019-09-05 | Janssen Research & Development, LLC | $539 | Research payment | Cash or cash equivalent | DARZALEX Biological, Oncology | A Phase I-II Trial of Daratumumab for the Treatment of Patients with AL amyloidosis | 2019 |
| 2019-09-03 | Boston Scientific Corporation | $450 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | PREEMPT HF | 2019 |
| 2019-09-02 | Janssen Research & Development, LLC | $750 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-08-30 | PFIZER INC. | $99,817 | Research payment | Cash or cash equivalent | BIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA | 2019 | |
| 2019-08-30 | PFIZER INC. | $66,703 | Research payment | Cash or cash equivalent | BIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA | 2019 | |
| 2019-08-30 | Integra LifeSciences Corporation | $8,146 | Research payment | Cash or cash equivalent | PRIMATRIX Device, RECON-SKIN AND WOUND | T-PMXDFU-01 | 2019 |
| 2019-08-30 | C. R. Bard, Inc. & Subsidiaries | $1,800 | Research payment | Cash or cash equivalent | ARCTIC SUN Device, MEDICAL SYSTEMS | INTREPID BMD1111 | 2019 |
| 2019-08-30 | ABBVIE INC. | $1,791 | Research payment | Cash or cash equivalent | M16-123 | 2019 | |
| 2019-08-29 | PFIZER INC. | $27,674 | Research payment | Cash or cash equivalent | DEVELOPING NEUTRALIZING SLIT23 MAB FOR TREATMENT OF GLOMERULAR DISEASES SUCH AS FOCAL SEGMENTAL GLOMERULOSCLEROSIS FSGS | 2019 | |
| 2019-08-29 | Laminate Medical Technologies inc. | $17,706 | Research payment | Cash or cash equivalent | Device, B | A Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous | 2019 |
| 2019-08-28 | Merck Sharp & Dohme LLC | $82,374 | Research payment | Cash or cash equivalent | JANUVIA Drug, ENDOCRINOLOGY | Effect of cardiac SGLT inhibition on cardiac energetics and hemodynamic function in type II diabetes | 2019 |
| 2019-08-28 | Conformis, Inc. | $1,911 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2019 |
| 2019-08-27 | Exelixis Inc. | $4,500 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor | 2019 |
| 2019-08-27 | Intercept Pharmaceuticals, Inc. | $2,051 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-08-27 | Exelixis Inc. | $122 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor | 2019 |
| 2019-08-27 | Exelixis Inc. | $25 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor | 2019 |
| 2019-08-26 | Janssen Research & Development, LLC | $4,836 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-08-22 | C. R. Bard, Inc. & Subsidiaries | $16,434 | Research payment | Cash or cash equivalent | ARCTIC SUN Device, MEDICAL SYSTEMS | INTREPID BMD1111 | 2019 |
| 2019-08-22 | Roche TCRC, Inc. | $7,704 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | THE EFFECT OF 24WEEK TREATMENT WITH BASMISANIL ON COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA | 2019 |
| 2019-08-22 | Roche TCRC, Inc. | $2,600 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | THE EFFECT OF 24WEEK TREATMENT WITH BASMISANIL ON COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA | 2019 |
| 2019-08-22 | Roche TCRC, Inc. | $1,584 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | THE EFFECT OF 24WEEK TREATMENT WITH BASMISANIL ON COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA | 2019 |
| 2019-08-22 | Roche TCRC, Inc. | $1,178 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | THE EFFECT OF 24WEEK TREATMENT WITH BASMISANIL ON COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA | 2019 |
| 2019-08-21 | Gilead Sciences, Inc. | $2,748 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Tra | 2019 |
| 2019-08-20 | Merck Sharp & Dohme LLC | $16,239 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2019 |
| 2019-08-20 | Medical Device Business Services, Inc. | $1,911 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow-up | 2019 |
| 2019-08-15 | Intercept Pharmaceuticals, Inc. | $750 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-08-15 | Janssen Research & Development, LLC | $250 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-08-14 | Conformis, Inc. | $9,750 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2019 |
| 2019-08-12 | Bayer Healthcare Pharmaceuticals Inc. | $2,885 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2019 |
| 2019-08-09 | Janssen Research & Development, LLC | $250 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2019 | |
| 2019-08-09 | Janssen Research & Development, LLC | $250 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-08-08 | Acorda Therapeutics, Inc | $318 | Research payment | Cash or cash equivalent | A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 Levodopa Inhalation Powder in Park | 2019 | |
| 2019-08-08 | Incyte Corporation | $171 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $171 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $133 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $103 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $85 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $61 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $53 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $52 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $28 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $25 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $21 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $21 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $21 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $15 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-08 | Incyte Corporation | $1 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2019 | |
| 2019-08-06 | PFIZER INC. | $27,674 | Research payment | Cash or cash equivalent | DEVELOPING NEUTRALIZING SLIT23 MAB FOR TREATMENT OF GLOMERULAR DISEASES SUCH AS FOCAL SEGMENTAL GLOMERULOSCLEROSIS FSGS | 2019 | |
| 2019-08-06 | ABBVIE INC. | $2,854 | Research payment | Cash or cash equivalent | M16-123 | 2019 | |
| 2019-08-06 | Medical Device Business Services, Inc. | $943 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow-up | 2019 |
| 2019-08-06 | ABBVIE INC. | $877 | Research payment | Cash or cash equivalent | M16-123 | 2019 | |
| 2019-08-06 | ABBVIE INC. | $582 | Research payment | Cash or cash equivalent | M16-123 | 2019 | |
| 2019-08-06 | ABBVIE INC. | $351 | Research payment | Cash or cash equivalent | M14-748 | 2019 | |
| 2019-08-01 | Janssen Research & Development, LLC | $4,278 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-08-01 | Shire North American Group Inc | $754 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2019 |
| 2019-08-01 | Shire North American Group Inc | $754 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2019 |
| 2019-08-01 | Shire North American Group Inc | $754 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2019 |
| 2019-08-01 | Shire North American Group Inc | $452 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2019 |
| 2019-07-31 | Conformis, Inc. | $877 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2019 |
| 2019-07-30 | ABBVIE INC. | $895 | Research payment | Cash or cash equivalent | M16-123 | 2019 | |
| 2019-07-29 | Merck Sharp & Dohme LLC | $16,239 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-07-25 | Bio-Rad Laboratories, Inc. | $22 | Gift | Cash or cash equivalent | Platelia Device, Immunoenzymatic | 2019 | |
| 2019-07-22 | Gilead Sciences, Inc. | $250 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boo | 2019 |
| 2019-07-18 | Intercept Pharmaceuticals, Inc. | $1,372 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-07-18 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2019 |
| 2019-07-11 | C. R. Bard, Inc. & Subsidiaries | $442 | Research payment | In-kind items and services | ARCTIC SUN Device, MEDICAL SYSTEMS | INTREPID BMD1111 | 2019 |
| 2019-07-08 | Gilead Sciences, Inc. | $975 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of FTC/TAF and | 2019 |
| 2019-07-05 | Janssen Research & Development, LLC | $11,113 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-07-03 | Merck Sharp & Dohme LLC | $191 | Research payment | In-kind items and services | PIFELTRO Drug, INFECTIOUS DISEASE | Phase I,II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine MK-1439 and Doravirine,Lamivudine,Tenofo | 2019 |
| 2019-07-01 | PFIZER INC. | $48,868 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-07-01 | Shire North American Group Inc | $7,709 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2019 |
| 2019-06-30 | Roche Diagnostics Corporation | $290 | Research payment | In-kind items and services | CD cobas Reagents Device, Centralized Diagnostics | RD001469 | 2019 |
| 2019-06-27 | Baxter Healthcare | $35,800 | Consulting Fee | Cash or cash equivalent | IPS - Liquid Premix Biological, Integrated Pharmacy Solutions | 2019 | |
| 2019-06-27 | Janssen Research & Development, LLC | $1,750 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2019 | |
| 2019-06-27 | ABBVIE INC. | $1,535 | Research payment | Cash or cash equivalent | M16-123 | 2019 | |
| 2019-06-26 | Merck Sharp & Dohme LLC | $300 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2019 |
| 2019-06-26 | Merck Sharp & Dohme LLC | $300 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamid | 2019 |
| 2019-06-26 | Merck Sharp & Dohme LLC | $300 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2019 |
| 2019-06-22 | Olympus Corporation of the Americas | $13,523 | Grant | In-kind items and services | Olympus ENT Instruments Device, ENT Products | 2019 | |
| 2019-06-19 | Gilead Sciences, Inc. | $1,056 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Tra | 2019 |
| 2019-06-13 | Alexion Pharmaceuticals, Inc. | $150 | Research payment | Cash or cash equivalent | Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Nave Adult and Adolescent Patients With Atypical Hemolyti | 2019 | |
| 2019-06-03 | Medical Device Business Services, Inc. | $390 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow-up | 2019 |
| 2019-05-30 | Philips North America LLC | $35,811 | Research payment | Cash or cash equivalent | US Undivided Serv Device, Cardiology/Vascular Diseases | VM6.0 | 2019 |
| 2019-05-29 | Gilead Sciences, Inc. | $5,480 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen containing Do | 2019 |
| 2019-05-29 | ABBVIE INC. | $895 | Research payment | Cash or cash equivalent | M16-123 | 2019 | |
| 2019-05-28 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-05-27 | Janssen Research & Development, LLC | $18,310 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-05-23 | Bayer Healthcare Pharmaceuticals Inc. | $1,625 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2019 |
| 2019-05-23 | Intercept Pharmaceuticals, Inc. | $1,046 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-05-23 | Merck Sharp & Dohme LLC | $213 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2019 |
| 2019-05-22 | Gilead Sciences, Inc. | $5,226 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boo | 2019 |
| 2019-05-22 | Merck Sharp & Dohme LLC | $2,120 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2019 |
| 2019-05-22 | Gilead Sciences, Inc. | $1,056 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Tra | 2019 |
The latest 200 records of 298.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
In Massachusetts; placed by its state only.
| Measure | State Massachusetts |
|---|---|
| Population B01003 | 7,044,056 |
| Population, 2020 census P1 | 7,029,917 |
| Median age B01002 | 40.0 |
| Under 18 B01001 | 19.4% |
| 65 and over B01001 | 17.9% |
| Households B11001 | 2,785,042 |
| Foreign born B05002 | 18.0% |
| Median household income B19013 | $103,960 |
| Median family income B19113 | $131,675 |
| Per capita income B19301 | $57,897 |
| Poverty rate B17001 | 10.0% |
| Unemployment rate B23025 | 5.2% |
| Civilian labor force B23025 | 3,911,446 |
| Mean commute (minutes) B08013 | 29.1 |
| Bachelor's degree or higher B15003 | 47.3% |
| Housing units B25001 | 3,030,406 |
| Owner-occupied B25003 | 62.5% |
| Renters B25003 | 37.5% |
| Median home value B25077 | $562,100 |
| Median gross rent B25064 | $1,762 |
| White, not Hispanic B03002 | 66.6% |
| Black B03002 | 6.4% |
| Hispanic or Latino B03002 | 13.3% |
| Asian B03002 | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Massachusetts.
Comments